IQ-AI Limited Advances Promising Cancer Drug
Company Announcements

IQ-AI Limited Advances Promising Cancer Drug

IQ-AI Limited (GB:IQAI) has released an update.

IQ-AI Limited has shared promising results from their Phase 1 clinical trial of oral gallium maltolate for treating glioblastoma, with some patients showing no disease progression for over six months. The company is preparing for a Phase 2 trial estimated at $2-2.5 million, aiming to start in 2025 with more extensive patient enrollment and a focus on overall survival. IQ-AI holds exclusive rights for commercialization and is looking to strengthen its IP position while considering future partnerships post-Phase 2 success.

For further insights into GB:IQAI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskIQ-AI Limited Eyes Revenue Growth and New Partnerships
TipRanks UK Auto-Generated NewsdeskBraveheart Investment Group Acquires Major Stake in IQ-AI Limited
TipRanks UK Auto-Generated NewsdeskIQ-AI Limited Reports Progress and New Milestones
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App